Home Newsfeeds Atea Pharmaceuticals Q3 EPS $(0.10) Beats $(0.44) Estimate

Atea Pharmaceuticals Q3 EPS $(0.10) Beats $(0.44) Estimate

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.44) by 77.27 percent. This is a 70.59 percent increase over losses of $(0.34) per share

byBenzinga Newsdesk

November 7, 2022

1 minute read

Earnings

Anheuser-Busch InBev: Q3 Earnings Insights

By Benzinga Insights

October 27, 5:35 AM

Anheuser-Busch InBev (NYSE:BUD) reported its Q3 earnings results on Thursday, October 27, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings Anheuser-Busch InBev reported in-line EPS of $0.84 versus an estimate of $0.84.

BUD

US Banks Witness Whopping $100 Billion Deposit Drop In Just Three Weeks, Fed Survey Raises Alarm

By Bibhu Pattnaik

October 28, 3:33 PM

Recent data reveals a substantial exodus of deposits from U.S. banks, increasing apprehensions about the robustness of the nation's financial institutions.

BAC

Gold Surges Over 1%; Biodesix Shares Plummet

By Avi Kapoor

Today, 12:06 PM

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Friday. The Dow traded up 1.01% to 38,987.23 while the NASDAQ rose 1.50% to 16,289.37. The S&P 500 also rose, gaining, 1.29% to 5,213.49.

BDSX

RBC Capital Maintains Outperform on Emerson Electric, Lowers Price Target to $107

By Benzinga Newsdesk

February 9, 10:08 AM

RBC Capital analyst Deane Dray maintains Emerson Electric (NYSE:EMR) with a Outperform and lowers the price target from $110 to $107.

EMR

Atea Pharmaceuticals Q3 EPS $(0.10) Beats $(0.44) Estimate

Related Posts

Anheuser-Busch InBev: Q3 Earnings Insights

US Banks Witness Whopping $100 Billion Deposit Drop In Just Three Weeks, Fed Survey Raises Alarm

Gold Surges Over 1%; Biodesix Shares Plummet

RBC Capital Maintains Outperform on Emerson Electric, Lowers Price Target to $107